Company profile
NextCure, Inc.
NASDAQ:NXTCBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NC-410 | phase1_2 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06774963 | phase1 | recruiting | 2025-01-07 | 2026-12-01 | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid Tumors |
| NCT06792552 | phase1 | recruiting | 2025-02-26 | 2028-02-01 | NextCure, Inc. | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors |
| NCT04430933 | phase1_2 | withdrawn | 2021-12-06 | 2022-06-30 | NextCure, Inc. | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC |
| NCT03665285 | phase1_2 | completed | 2018-10-01 | 2023-04-11 | NextCure, Inc. | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors |
| NCT04408599 | phase1_2 | terminated | 2020-06-10 | 2023-07-06 | NextCure, Inc. | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors |
FDA applications (0)
No records yet.